ArticleBMC nephrology2026
The relationship between serum zinc level and prognosis of non-dialysis CKD patients.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) constitutes a major public health challenge. Zinc deficiency is highly prevalent among CKD patients and is closely associated with the progression of kidney impairment. However, research focusing on serum zinc levels in non-dialysis chronic kidney disease (ND-CKD) patients remains limited.
methodsA single-center retrospective study was conducted on patients diagnosed with ND-CKD in the Department of Nephrology, General Hospital of Ningxia Medical University from October 2021 to December 2024. Participants were categorized into quartiles based on serum zinc levels, and clinical characteristics along with prognostic outcomes were compared across these groups.
resultsThe study included 206 ND-CKD patients. The median serum zinc level was 11.49(10.57,13.29) µmol/L. Over a median follow-up of 36 months, 46 patients (22.3%) experienced endpoint events. Comparative analysis revealed that ND-CKD patients with lower serum zinc levels had a significantly reduced survival rate (P < 0.05). Restricted Cubic Spline analysis confirmed a non-linear relationship between serum zinc levels and prognosis, as serum zinc levels increased, the hazard ratio(HR) gradually decreased and eventually plateaued or exhibited a slight increase (P < 0.001). Further analysis using a Trajectory model showed that the prognosis of high serum zinc level and slow decline group (class2) was significantly better than that of low serum zinc level and rapid decline group (class1) (P = 0.002, 0.23 (0.09, 0.58)).
conclusionIn the subgroup of ND-CKD patients with clinical indications, low serum zinc level was independently associated with poor renal prognosis and was a significant predictor of clinical outcome. Serum zinc levels gradually decline as ND-CKD progresses, lower serum zinc levels are correlated with an increased risk of endpoint events and a poorer prognosis. However, as this is a single‑center retrospective study, the generalizability of the findings may be limited, and prospective multicenter validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.